Devicor Completes Acquisition of Neoprobe Products and Related Assets

Julie Ritzer Ross | | Radiology Business | Business Intelligence
Devicor™ Medical Products, Inc., a portfolio company of Chicago, Illinois-based private equity firm GCTR, last week announced the execution of its previously revealed agreement to acquire the neoprobe® gamma detection system (GDS) products and related assets from Neoprobe Corporation. Devicor had previously provided distribution and marketing services to Neoprobe for the GDS portfolio. Financial terms of the agreement included $30 million cash at close, plus up to an additional $20 million in royalties based on revenue milestones. The sale was approved by Neoprobe's shareholders on August 15. The acquisition of the neoprobe® GDS line comes approximately one year after Devicor's acquisition of Ethicon Endo-Surgery's (EES) Breast Care business, Mammotome, which sells products designed to aid in the detection and diagnosis of breast cancer. GTCR invested additional equity capital in Devicor to finance a portion of the purchase price of the neoprobe® GDS assets. To read the press release, click here: http://www.prnewswire.com/news-releases/devicor-medical-products-inc-completes-acquisition-of-neoprobes-gamma-detection-devices-127968843.htm

Julie Ritzer Ross,

Contributor

Related Content

Orano Med breaks ground on $265M thorium production site
Image-interpretation market scoreboard: Radiologists 72%, others 28%
Lantheus lands rights to budding radiopharmaceuticals for initial outlay of $35M
17 short-term strategies to address the national radiologist shortage
‘SR’ onboards another independent practice, its 1st in the Natural State
Analysis: Allied radiology professionals generate millions of dollars per year in indirect revenues alone

Around the web

Health Imaging
Nearly $800,000 settlement offered to family of man who died during MRI exam

The patient, who was being cared for in the ICU, was not accompanied or monitored by nursing staff during his exam, despite being sedated.

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.